Electronic Logs - The next phase of execution maturity in pharma
Clinically Validated Probiotics
Why Sustainable Biomanufacturing Must Start Earlier in The Process
Maximising Patient Engagement in Clinical Trials
Complex Journey from Innovation to Patient impact
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Rise of Enabling Technologies in Pharmaceutical Formulation Development and Manufacturing
Director, Formulation Development, Exelixis, Inc
Kasturi Pawar is a leading pharmaceutical scientist with a PhD in pharmaceutical sciences She has significantly contributed to the field of pharmaceutics Her research and experience have been focused on formulation development drug delivery and clinical supply chain Currently working as a Director in Formulation Development at Exelixis Inc she holds several publications and patents on drug deliver...
Articles
Evolution of eCTD from version 1 to 4
The electronic Common Technical Document eCTD has undergone significant evolution from its inception to the current version The eCTD standard is primarily used for the submission of regulatory information to health authorities providing a structured electronic format for regulatory submissions
Research Insights
FARE-CAFE: a database of functional and regulatory elements of cancer-associated fusion events
Abstract Chromosomal translocation CT is of enormous clinical interest because this disorder is associated with various major solid tumors and leukemia A tumorspecific fusion gene event may occur when a translocation joins two separate genes Currently various CT databases provide information about fusion genes and their genomic elements However no database o
Case Studies
Remarkable Regression Of A Giant Cell Tumor Of The Cervical Spinetreated Conservatively With Denosumab: A Case Study
Abstract This case study has been conducted to establish the fact that Denosumab can be used as an adjuvant therapy by which to avoid or reduce the risks and morbidity of surgical treatment in patients with spinal GCTs extending into the nearby tissues considering the adequate duration safety and lack of adverse events of this treatment even though further
Techno Trends
Kansas City University Discovered New Cancer Treatment
Researchers at Kansas City University have made a breakthrough in treating pancreatic cancer by repurposing the FDAapproved drug Acipimox originally designed to treat hyperlipidaemia
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Magnetic Nanoparticles and their Application Studies on Synthesis Characterisation
Prabhanjan S Giram qualified CSIR-NET AIR-81 in chemical sciences and received his Ph. D from National chemical laboratory, Pune. He Received Eudragit® 2018 Award of 1500 Euros from Evonik health care Germany. He also received newton Bhabha Fellowship from British council, UK and DBT, India. He has expertise in synthesis of biocompatible, biodegradable polymer with rationalised design of nanoformulation, nanofiber, semisolid dosage form such as ointment, creams, and gel.
Shubham R Musale has graduate in pharmacy from Savitribai Phule Pune University. He got fellowship for M.pharm from AICTE. The Thesis titled for M.pharm Design of In-expensive Collector for preparation Electrospun Nanofiber. He has 2 review publication and 1 Book Chapter.
Sushil Y Raut has over 12 years of teaching and research experience. He has more than 25 research and review publications. He filed 3 Indian patents and over 20 national as well as international presentations in his credits. He is recipient of international research mobility fellowship and other prestigious awards.
The Transformative Impact of AI on Regulatory Affairs
Yu Han, DPhil in Engineering Science from the University of Oxford, brings a rich background with experience at manufacturer, global regulatory affairs CRO, and AI sector. Her expertise spans the regulatory landscapes of Asia, the US, and the EU, providing a comprehensive understanding of global pharmaceutical regulations. Passionate about combining AI technology with healthcare, Yu excels in creating innovative engineering tools to advance medical solutions. Her work leverages engineering methodologies to unravel complexities in the medical listing process, streamlining the global product flow.
<p> </p>
Email: yu.han@eng.ox.ac.uk
Endocrine Disrupting Compounds (EDCs)
Sintu Kumar Samanta has been working as an Assistant professor in IIIT Allahabad, India. He did Ph.D. and post-doctoral research from IIT Kharagpur and IISc Bangalore, India respectively. He is working in the area of Biochemistry and Nanobiotechnology. He published research work in several international journals and filed one Indian patent.
Pavan Kumar Gautamis presently working as a Post-Doctoral Fellow in the Department of Applied Sciences at IIIT Allahabad, India. He obtained Ph.D. from the University of Allahabad, India. His area of research is synthesis of nanoparticles for water remediation. He published his research work in many international journals.
M&A, Partnerships & Ecosystem Models in Biopharma
Surbhi Gupta is an Industry Principal at Frost & Sullivan with extensive experience in global pharmaceutical and biotech market research and consulting. She leads the Biopharma Therapeutics program, focusing on next-generation modalities and precision medicine. Her work spans market analytics, forecasting, competitive benchmarking, and strategy support for biopharma clients globally.
Innovative Tool For Drug Design And Development
S.Subash awarded 2 best poster presentation awards and secured 1st place in Poster presentation. I published three articles in national and international peer reviewed journal. And, also attend many conferences to upgrade knowledge.
press releasesRead more...
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
EventsRead more...
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
LATEST NEWSRead more...
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
